autologous anti-CD83 CAR T-cells

Autologous anti-CD83 CAR T-cells are an investigational genetically engineered cell therapy designed to treat relapsed or refractory acute myeloid leukemia (AML). The therapy involves harvesting a patient's own T cells and modifying them to express a chimeric antigen receptor (CAR) that targets CD83, a protein expressed on AML blasts (abnormal immature white blood cells). Beyond its role as a tumor-associated antigen in AML, CD83 is also expressed on mature dendritic cells that mediate graft-versus-host disease (GVHD). By targeting CD83, this therapy aims to achieve dual therapeutic goals: the direct cytotoxic elimination of leukemia cells and the potential prevention or mitigation of GVHD and myeloid aplasia, which are common complications in patients undergoing hematopoietic stem cell transplantation.

Other names

CD83 CAR T cellsCD-83 CAR T cellsCD 83 CAR T cellsCD83-directed CAR T-cellsCD-83-directed CAR T-cellsCD 83-directed CAR T-cellshuman CD83 CAR T cells